EBR Systems makes the WiSE CRT System, its only product — an implantable cardiac pacing device that delivers left ventricular pacing without a lead (wire). Conventional cardiac resynchronization therapy (CRT) devices use leads to pace the left ventricle in heart failure patients whose ventricles beat out of sync, but leads are the primary point of failure in these systems. WiSE replaces the lead with ultrasound: a transmitter implanted under the skin picks up a signal from a co-implanted pacemaker or ICD, then emits an ultrasonic pulse to a small electrode in the left ventricle, which converts that energy into an electrical stimulus, achieving biventricular pacing. WiSE is approved for patients who cannot receive conventional CRT — either because a prior lead implant failed, or because a standard CRT upgrade carries elevated risk. EBR sells WiSE directly to hospitals on a per-procedure basis, with each implant requiring a set of disposable and durable components. The company is currently in a Limited Market Release in the U.S., targeting high-volume hospitals that participated in its SOLVE-CRT clinical trial, with a full U.S. market release planned for the second half of 2026 and international expansion into Australia, the UK, and the EU to follow. CMS has established reimbursement pathways covering WiSE in both inpatient and outpatient settings, effective for three years from October 2025. EBR holds 59 granted U.S. patents covering its core technology, and has no direct competitor for its approved indications.